Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2020 | Next questions for mantle cell lymphoma

Jonathon Cohen • 9 Sep 2020
SOHO 2020
Lymphoma Mantle Cell Lymphoma CAR-T

Jonathon B. Cohen, MD, MS, of Winship Cancer Institute of Emory University, Atlanta, GA, outlines the next questions in mantle cell lymphoma, including a greater understanding of the requirement of frontline therapies, the management of disease using minimal residual measurements, as well as identifying patients appropriate for CAR T-cell therapies. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Jonathon Cohen

0:57
Immunotherapeutic approaches for MCL patients who progress following BTKi treatment
Jonathon Cohen • 11 Dec 2023
0:49
Outcomes of patients with MCL who require urgent treatment at time of diagnosis
Jonathon Cohen • 11 Dec 2023
0:55
A pooled analysis to determine the optimal Ki-67 index cut-off point for predicting outcomes in MCL
Jonathon Cohen • 11 Dec 2023
0:55
Updated results of the BRUIN trial: pirtobrutinib in R/R MCL
Jonathon Cohen • 11 Dec 2023

Related Videos

1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
2:28
Checkpoint inhibitors vs brentuximab vedotin as salvage therapy prior to alloSCT for HL
Jacopo Mariotti • 15 Apr 2024
1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals